Literature DB >> 6849222

Influence of tachycardia cycle length and antiarrhythmic drugs on pacing termination and acceleration of ventricular tachycardia.

G V Naccarelli, D P Zipes, G T Rahilly, J J Heger, E N Prystowsky.   

Abstract

We examined the influence of ventricular tachycardia (VT) cycle length and antiarrhythmic drugs on the frequency of VT termination and acceleration by single and double extrastimuli and right ventricular burst pacing. In 57 patients, 89 episodes of sustained VT (32 control, 57 drug) were induced by programmed electrical stimulation. Overall, 60 of 89 (67%) episodes of ventricular tachycardia were terminated by means of programmed electrical stimulation. In patients with relatively slow ventricular tachycardia (VT cycle length greater than or equal to 350 msec) pacing terminated 37 of 44 (84%) episodes but terminated only 24 of 45 (51%) episodes of more rapid VT (VT cycle length less than or equal to 349 msec, p less than 0.005). Pacing successfully terminated VT in nine of 49 (18%) episodes using a single extrastimulus, 22 of 52 (42%) episodes using double extrastimuli, and 40 of 66 (61%) episodes using burst right ventricular pacing. VT acceleration occurred in none of 49 attempts with a single extrastimulus, in eight of 52 (15%) attempts with double extrastimuli, and in 12 of 66 (18%) attempts using burst right ventricular pacing. During therapy, the frequency of either ventricular tachycardia termination or acceleration did not change regardless of the pacing termination method used. However, by prolonging the mean VT cycle length from 311.1 +/- 82.2 msec to 401.9 +/- 103.5 msec (p less than 0.01), drugs increased the overall frequency of VT termination. We conclude that: (1) pacing terminates VT more frequently if the VT cycle length is long and if right ventricular bursts are used, (2) burst right ventricular pacing increases the risk of VT acceleration, and (3) drugs increase the frequency of ventricular tachycardia termination by prolonging VT cycle length but do not affect frequency of VT acceleration.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6849222     DOI: 10.1016/0002-8703(83)90269-7

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  8 in total

Review 1.  Role of substrate and triggers in the genesis of cardiac alternans, from the myocyte to the whole heart: implications for therapy.

Authors:  Faisal M Merchant; Antonis A Armoundas
Journal:  Circulation       Date:  2012-01-24       Impact factor: 29.690

2.  Therapeutic options in the management of life-threatening arrhythmias.

Authors:  J M Herre; J C Griffin
Journal:  West J Med       Date:  1989-07

3.  Recent trends in the management of life-threatening ventricular arrhythmias.

Authors:  B N Singh; J N Weiss; K Nademanee; J H Wittig; P Guzy
Journal:  West J Med       Date:  1984-11

Review 4.  Interactions of antiarrhythmic drugs with implantable defibrillator therapy for atrial and ventricular tachyarrhythmias.

Authors:  R B Krol; S Saksena; A Prakash
Journal:  Curr Cardiol Rep       Date:  1999-11       Impact factor: 2.931

5.  Drug-induced narrowing of the width of the zone of entrainment as a predictor of the subsequent non-inducibility of reentrant ventricular tachycardia after an additional dose of an antiarrhythmic drug.

Authors:  Y Aizawa; M Chinushi; N Naitoh; A Shibata
Journal:  Heart       Date:  1996-02       Impact factor: 5.994

6.  Efficacy of a tiered therapy defibrillator system used to treat recurrent ventricular arrhythmias refractory to drugs.

Authors:  A C Rankin; S Zaim; A Powell; B Zaim; R Brooks; B A McGovern; H Garan; J N Ruskin
Journal:  Br Heart J       Date:  1993-07

Review 7.  Rationale and patient selection for "hybrid" drug and device therapy in atrial and ventricular arrhythmias.

Authors:  A John Camm; Irina Savelieva
Journal:  J Interv Card Electrophysiol       Date:  2003-10       Impact factor: 1.900

8.  Internal transvenous low energy cardioversion for the treatment of cardiac arrhythmias.

Authors:  A W Nathan; R S Bexton; R A Spurrell; A J Camm
Journal:  Br Heart J       Date:  1984-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.